Skip to content

Ceres Pharmaceuticals

Active Public limited companyfounded 1970active for 56 yearsKortrijksesteenweg 1091, 9051 GhentKBO/BCE: BE 0407.326.754 subsidiary of
Part of the group 27 companies in 10 countries

Lifetime

20 annual accounts with figures on one time axis, 49 filings since 1978
peak of €14.6m in 2025
€14.6m▲ 17.1%
lowest -€300,447 in 2023
€2.6m▲ €2.7m
peak of €3.1m in 2022
€1.3m▼ 50.8%
€8.1m▲ 298%
peak of 24.3 FTE in 2023
17.6 FTE▼ 26.4%
Board3 names since 2024
2 directors and 1 other
Owners4 names in the annual accounts
100% and 1 other
Documentsfilings and deeds
22-07-20269 days before the deadline
2025financial year
Turnover from €12.5m to €14.6mProfit of €2.6m, after a lossStaff from 23.9 FTE to 17.6 FTECompany renamed from KELA PHARMA to Ceres Pharmaceuticals 12-05Registered office moved from Hoogstraten to Sint-Denijs-Westrem 24-01Dividend €4.0m

Key points

from the 2025 annual accounts

Equity

€1.3m ▼ 50.8%
2.72024+2.6Profit-4.0Dividend1.32025

Ceres Pharmaceuticals paid out €4.0m in dividends. That is 152% of the 2025 profit.

Result

€2.6m €2.6m
-€99,2002024€2.6m2025

Back in profit in 2025, after a loss of €99,159 in 2024.

Debts

€8.1m 86% of the balance sheet
Suppliers 29%Taxes and wages 19%Other 52%

Of this, €8.0m falls due within a year.

Securities

€1.9m

The 2025 accounts state a pledge on other assets of €1.9m, 1.5 times equity. The 2024 accounts did not.

Investments

€22,519 6.1 times depreciation
2021202220232025

Green is investment, beige is depreciation.

Payment terms

98 days to suppliers
Suppliers
43 to 98
Customers
38 to 47

Ceres Pharmaceuticals pays its suppliers 55 days later than in 2024. Customers pay 9 days later.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,615 companies had the same profile as Ceres Pharmaceuticals has now. Each dot stands for 7 companies, two years later.

97.3%
were still trading
2.0%
stopped another way
0.7%
went bankrupt
  • Small
  • 20 years or older
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,615 companies, not a prediction for Ceres Pharmaceuticals. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 20-12-2024
Director, , since 20-12-2024
Auditor,
  • 100%score equity -€1.6m (2025) · annual accounts 2025 of
Board & ownership

Recent changes

1 statutory auditor appointed (statutory auditor) · and act as permanent representatives · General meeting of 11-06-2025 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0407326754
Company renamed from KELA PHARMA to Ceres Pharmaceuticals General meeting of 06-05-2025 · Gazette deed
Registered office moved from Hoogstraten to Sint-Denijs-Westrem The registered office moved from Sint Lenaartseweg 48, 2320 Hoogstraten to Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem · resigns as sole director · , and act as permanent representatives · General meeting of 20-12-2024 · Gazette deed
All 73 events

Comparable companies

same main activity, similar in size and age
Company
Ceres Pharmaceuticals Ghent €14.6m 24.6% 13.9% 17.6
Revogan Ghent €17.8m 3.2% 42.1% 21.5
ZAMBON Jette €18.8m 10.2% 38.5% 20.8
TELEFLEX MEDICAL Brussels €18.7m 3.2% 40.9% 16.8
LAGAE JOZEF EN ZONEN - VLASHANDEL EN - NIJVERHEID - LAGAE JOSEPH ET FILS - COMMERCE ET INDUSTRIE DU LIN Kuurne €16.5m -0.2% 10.0% 25.1
Filter Service Eupen €13.0m 2.5% 74.8% 29.4
DECHRA VETERINARY PRODUCTS Herentals €20.5m 3.3% 12.0% 15.9
-10%0%10%20%€20m€200m€2bn€20bnCeres PharmaceuticalsEBIT margin

Grey: the largest companies of the sector (wholesale trade (NACE 46)), without their names. Blue: the sector peers from the table.

These companies have the same main activity as Ceres Pharmaceuticals: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €5.5m and €8.9m, founded between 1956 and 1971.

Official details

Source: KBO
Status
Active since 23-09-1970Normal situation
Registered office
23 active companies are registered at this addressSource: KBO register, as of 20 November 2026.
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460and 1 other
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.318.638.4119051 Ghent, registered on 27-05-2021
Financial year end
31 December
Peppol
Reachable since 01-08-2025
Company details

Annual accounts 2025

€9.5m▲ 100%
Employeeson 31-12-2025
17▼ 29.2%
Filing
Filed on 22-07-2026, 9 days before the end of the filing period
Financials

Companies linked to Ceres Pharmaceuticals

Parent and group

Insights on Ceres Pharmaceuticals

Ceres Pharmaceuticals has existed since 1970. Turnover grew from €5.8m in 2006 to €14.6m in 2025.

Solvency fell in 2025 from 56.7% to 13.9% because of the dividend.

holds all the shares. In January 2024, three directors stepped down.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Ceres Pharmaceuticals

What is the company number of Ceres Pharmaceuticals?
The company number of Ceres Pharmaceuticals is 0407.326.754. The VAT number is the same number with BE in front: BE 0407.326.754.
Where is Ceres Pharmaceuticals based?
The registered office is at Kortrijksesteenweg 1091, 9051 Ghent.Company details
What does Ceres Pharmaceuticals do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of Ceres Pharmaceuticals?
Ceres Pharmaceuticals is a public limited company (NV).
When was Ceres Pharmaceuticals founded?
Ceres Pharmaceuticals was founded on 23-09-1970.
Is Ceres Pharmaceuticals still active?
Yes, Ceres Pharmaceuticals is an active enterprise in the KBO register.
How many employees does Ceres Pharmaceuticals have?
Ceres Pharmaceuticals had an average of 17.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does Ceres Pharmaceuticals fall under?
In its 2025 annual accounts, Ceres Pharmaceuticals states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of Ceres Pharmaceuticals?
The turnover of Ceres Pharmaceuticals was €14.6m in financial year 2025, according to the filed annual accounts.
Is Ceres Pharmaceuticals profitable?
In financial year 2025, Ceres Pharmaceuticals made a profit of €2.6m.
Where can I find the annual accounts of Ceres Pharmaceuticals?
Ceres Pharmaceuticals filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Ceres Pharmaceuticals due?
Ceres Pharmaceuticals must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.